Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.

Artificial intelligence (AI) vendors are partnering with health care providers to identify practical challenges and consider AI technology as a potential solution. This type of collaboration is crucial to successful AI adoption because the technology is designed to tackle real-world health care problems. A myriad of examples was displayed at the recent RSNA 2020 meeting.

The acquisitions of Alexion and Celgene are the latest in a long line of transactions in which big pharma buys big biotech. But these latest two are of biotechs that have disappointed their investors, and there are still some of those left for 2021.

A $70m fund will back prior investments, while a $430m fund will launch new biotech firms. Harper and Seidenberg tapped into their Amgen connections for the CEO who helms new company Acelyrin.